FDA
Orders where directed actors are tied to FDA · 9 in Search.
Roles directed
Orders
9 shown
Accelerating Medical Treatments for Serious Mental Illness
This executive order directs federal agencies to accelerate research, regulatory review, and patient access to psychedelic drugs (including ibogaine compounds) for treating serious mental illness and reducing suicide rates. It creates FDA priority vouchers for breakthrough-designated psychedelics, establishes Right to Try access pathways, funds state-federal collaboration through ARPA-H, mandates interagency data sharing with VA, and requires timely DEA rescheduling of approved psychedelic products.
Addressing Addiction Through the Great American Recovery Initiative
This executive order establishes the White House Great American Recovery Initiative, co-chaired by the Secretary of HHS and a Senior Advisor for Addiction Recovery, to coordinate federal response to substance use disorder. The Initiative brings together 15+ officials across cabinet departments and agencies to recommend steps for aligning federal programs, increasing treatment access, and integrating addiction services across health, criminal justice, workforce, education, and housing systems.
Increasing Medical Marijuana and Cannabidiol Research
This executive order directs the Attorney General to expedite rescheduling marijuana from Schedule I to Schedule III of the Controlled Substances Act to facilitate medical research. It also directs multiple health agencies to develop research methods using real-world evidence for medical marijuana and hemp-derived CBD products, and tasks White House legislative staff with working Congress to update statutory definitions for hemp-derived cannabinoids.
Regulatory Relief To Promote Domestic Production of Critical Medicines
This executive order directs federal agencies to streamline regulatory and permitting processes for domestic pharmaceutical manufacturing, with specific actions by FDA, EPA, Army Corps of Engineers, and OMB. It also mandates increased inspections and fees on foreign manufacturing facilities and requires public disclosure of foreign inspection data, aiming to reduce domestic facility construction timelines from 5-10 years and shift production back to the United States.
Promoting Competition in the American Economy
This executive order establishes a whole-of-government competition policy to combat excessive market concentration across the economy. It creates a White House Competition Council and directs dozens of specific actions by agencies including the FTC, DOJ, USDA, HHS, DOT, FCC, and others to address anti-competitive practices in labor markets, agriculture, healthcare, telecommunications, transportation, and technology.
An America-First Healthcare Plan
This executive order declares a continuation of healthcare policies emphasizing patient choice, lower costs, and quality care, with specific directives to maintain existing actions and new deadlines for price transparency and surprise billing measures. It requires HHS to work with Congress on surprise billing legislation by year-end 2020, take administrative action if legislation fails, and update Medicare.gov Hospital Compare within 180 days with hospital billing quality information.
Modernizing the Regulatory Framework for Agricultural Biotechnology Products
This executive order directs federal agencies to modernize regulations for agricultural biotechnology products, streamline oversight across USDA, EPA, and FDA, and promote both domestic public acceptance and international trade of genetically engineered crops and animals. It mandates specific plans for regulatory streamlining, a unified web-based platform for developers, consumer engagement strategies, and international trade barrier removal.
White House Cancer Moonshot Task Force
This memorandum establishes the White House Cancer Moonshot Task Force, chaired by the Vice President, to coordinate federal efforts to accelerate cancer research, treatment, and prevention. The Task Force includes heads of 14 executive departments and agencies and is directed to produce findings and recommendations on accelerating research, improving patient care, reducing regulatory barriers, and developing public-private partnerships, with a report due to the President by December 31, 2016.
Improving Health Protection of Military Personnel Participating in Particular Military Operations
This executive order establishes procedures for administering investigational drugs to military personnel during particular military operations when FDA-approved alternatives are unavailable. It creates a detailed waiver process for informed consent requirements under 10 U.S.C. 1107(f), requiring presidential approval, FDA consultation, ongoing monitoring, and congressional notification.